Angiotensin IV analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Each entry on this list of common misconceptions is worded as a correction; the misconceptions themselves are implied rather than stated. These entries are concise summaries; the main subject articles can be consulted for more detail.
== Histology == Skin samples under a microscope show thinned epidermis, reduced collagen, and extravasation of red blood cells. There are typically no inflammatory cells seen on solar purpura samples, but not always.
== Clinical research == Although lipoic acid has been tested in clinical research for potential use as a therapy for various diseases, the studies have been of limited quality, with no conclusive evidence that it is warranted as a therapeutic, as of 2026. According to the American Cancer Society as of 2013, "there is no reliable scientific evidence at this time that lipoic acid prevents the development or spread of cancer". As of 2015, intravenously administered ALA is unapproved anywhere in the world except Germany for diabetic neuropathy, but has been proven reasonably safe and effective. As of 2012, there was no good evidence alpha lipoic acid helps people with mitochondrial disorders. A 2018 review found that ALA had a small effect to reduce body weight, but is not cost-effective as a dietary supplement. A 2025 study indicated a positive effect in a cellular model of Friedreich's ataxia.
The Cuban activist and historian Emilio Roig de Leuchsenring wrote of Freemasonry in Cuba:"To fully express what Freemasonry represents for us in a few words, suffice to say that, without mentioning it once, twice and perhaps a thousand times, one cannot write the history of Cuban culture or Cuba's struggle for freedom."
=== 2006–2010 === In 2006, Sonic Healthcare acquired Central Queensland Pathology Laboratory (Mackay, Queensland) merging it with Sullivan Nicolaides Pathology, Muskogee Clinical Laboratory (Muskogee, Oklahoma, US), The Cognoscenti Health Institute (East Orlando, Florida, US), and Lookadoo Skyline Laboratories (Port St Lucie, Florida, US). Bioscientia Healthcare Group based in Ingelheim, Germany, August 2007. In 2007, the company acquired American Esoteric Laboratories (Tennessee and Texas), the remaining 18% of Clinical Pathology Laboratories, Mullins Pathology & Cytology Laboratory P.C., Augusta, Georgia, US, Sunrise Medical Laboratories, a full-service clinical reference laboratory servicing Long Island and the New York metropolitan area, and Woodbury Clinical Laboratory in Lebanon, Tennessee. That same year, in Europe, the Medica Laboratory Group, based in Zurich, Switzerland, the Bioscientia Healthcare Group in Ingelheim, Germany, and the remaining equity in the Schottdorf Group were acquired. In Australia, Sonic Healthcare acquired LifeCheck (Sydney, NSW), merging it into Lifescreen. In 2008, in the US, Sonic Healthcare acquired American Clinical Services (New Jersey) merging it with Sunrise Medical Laboratories, Clinical Laboratories of Hawaii, and Pan Pacific Pathologists (Hawaii). In Europe, it acquired Labor Prof. Krech (Switzerland) merging it into Medica, Labor 28 (Berlin, Germany), GLP Medical Group (Hamburg, Germany), and 100% ownership of IPN which in turn acquired the Gemini Medical Group.
Sources: en.wikipedia.org
=== Discontinued === Amibegron (SR-58611; SR-58611A) – β3-adrenergic receptor agonist [26] BTG-1640 (ABIO-08/01; ABIO-0801) – undefined mechanism of action [27] Darigabat (CVL-865; PF-06372865; PF-6372865) – GABAA receptor positive allosteric modulator [28] Imagabalin (PD-0332334; PD-332334; PF-00195889) – α2δ subunit-containing voltage-gated calcium channel ligand [29] Naluzotan (PRX-00023) – serotonin 5-HT1A receptor agonist and sigma σ1 receptor agonist [30] Ocinaplon (CL-273547) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/pyrazolopyrimidine [31] Pagoclone (IP-456; Panex; RP-62955) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [32] PF-572778 – undefined mechanism of action [33] Rufinamide (Banzel; CGP-33101; E-2080; Inovelon; RUF-331; SYN-111) – sodium channel blocker and other actions [34] Talaglumetad (LY-544344) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (eglumetad prodrug) [35] Tedatioxetine (Lu-AA24530) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), serotonin 5-HT2A, 5-HT2C, and 5-HT3 receptor antagonist, and α1A-adrenergic receptor antagonist [36]
== Background == Enzymes are proteins that catalyze (i.e. accelerate) chemical reactions. They are natural catalysts and are ubiquitous, in plants, animals and microorganisms where they catalyze processes that are vital to living organisms. They are intimately involved in numerous biotechnological processes, such as cheese making, beer brewing and winemaking, that date back to the dawn of civilization. Recent advances in biotechnology, particularly in genetic and protein engineering, and genetics have provided the basis for the efficient development of enzymes with improved properties for established applications and novel, tailor-made enzymes for completely new applications where enzymes were not previously used. Today, enzymes are widely applied in many different industries and the number of applications continues to increase. Examples include food (baking, dairy products, starch conversion) and beverage (beer, wine, fruit and vegetable juices) processing, animal feed, textiles, pulp and paper, detergents, biosensors, cosmetics, health care and nutrition, waste water treatment, pharmaceutical and chemical manufacture and, more recently, biofuels such as biodiesel. The main driver for the widespread application of enzymes is their small environmental footprint. Many traditional chemical conversions used in various industries suffer from inherent drawbacks from both an economic and environmental viewpoint. Non-specific reactions can afford low product yields, copious amounts of waste and impure products.
An individual with a transsexual or gender dysphoria diagnosis can, together with the assessment team and other doctors, decide what suits them. Medically transitioning in Sweden is covered by the high-cost protection for medications and doctor's visits, and there is no surgery fee. The fee the individual pays for a doctor's appointment or other care represents only a small fraction of the actual costs. If a person would like to change their legal gender marker and personal identity number they will have to seek permission from the National Board of Health and Welfare. For non-binary persons younger than 18 years, the healthcare is limited. These individuals do not have access to a legal gender marker change or bottom surgery. In Sweden, anyone is allowed to change their name at any time, including for gender transition. Up until January 27, 2017, being transsexual was classed as a disease. Two months earlier, on November 21, 2016, around 50 trans activists broke into and occupied the Swedish National Board of Health and Welfare (Swedish: Socialstyrelsen) premises in Rålambsvägen in Stockholm. The activists demanded that their voices be heard regarding the way the country, healthcare, and the National Board of Health and Welfare mistreat transgender and intersex individuals. Sweden's Karolinska Institute, administrator of the second-largest hospital system in the country, announced in March 2021 that it would discontinue providing puberty blockers or cross-sex hormones to children under 16.
The shark population has benefited significantly from the surge in seal numbers following the Marine Mammal Protection Act in 1972, and as many as 800 individual white sharks are documented visiting the Cape Cod area.
=== Works cited === Hotez PJ (2022). "12. The Newest NTDs and a Plea to "Repair the World"". Forgotten People, Forgotten Diseases: The Neglected Tropical Diseases and Their Impact on Global Health and Development (3 ed.). John Wiley & Sons. pp. 217–226. ISBN 978-1-68367-389-7.
Sources: en.wikipedia.org
The search for patterns in the variations of birds was attempted by many. Friedrich Wilhelm Joseph Schelling (1775–1854), his student Johann Baptist von Spix (1781–1826), and several others believed that a hidden and innate mathematical order existed in the forms of birds. They believed that a "natural" classification was available and superior to "artificial" ones. A particularly popular idea was the Quinarian system popularised by Nicholas Aylward Vigors (1785–1840), William Sharp Macleay (1792–1865), William Swainson, and others. The idea was that nature followed a "rule of five" with five groups nested hierarchically. Some had attempted a rule of four, but Johann Jakob Kaup (1803–1873) insisted that the number five was special, noting that other natural entities such as the senses also came in fives. He followed this idea and demonstrated his view of the order within the crow family. Where he failed to find five genera, he left a blank insisting that a new genus would be found to fill these gaps. These ideas were replaced by more complex "maps" of affinities in works by Hugh Edwin Strickland and Alfred Russel Wallace. A major advance was made by Max Fürbringer in 1888, who established a comprehensive phylogeny of birds based on anatomy, morphology, distribution, and biology. This was developed further by Hans Gadow and others. The Galapagos finches were especially influential in the development of Charles Darwin's theory of evolution.
=== Etymology === The word diabetes ( or ) comes from Latin diabētēs, which in turn comes from Ancient Greek διαβήτης (diabētēs), which literally means "a passer through; a siphon". Ancient Greek physician Aretaeus of Cappadocia (fl. 2nd century CE) used that word, with the intended meaning "excessive discharge of urine", as the name for the disease. Ultimately, the word comes from Greek διαβαίνειν (diabainein), meaning "to pass through", which is composed of δια- (dia-), meaning "through" and βαίνειν (bainein), meaning "to go". The word "diabetes" is first recorded in English, in the form diabete, in a medical text written around 1425. The word mellitus ( or ) comes from the classical Latin word mellītus, meaning "mellite" (i.e. sweetened with honey; honey-sweet). The Latin word comes from mell-, which comes from mel, meaning "honey"; sweetness; pleasant thing, and the suffix -ītus, whose meaning is the same as that of the English suffix "-ite". It was Thomas Willis who in 1675 added "mellitus" to the word "diabetes" as a designation for the disease, when he noticed the urine of a person with diabetes had a sweet taste (glycosuria). This sweet taste had been noticed in urine by the ancient Greeks, Chinese, Egyptians, and Indians.
==== Binge eating ==== Estrogen may play a role in suppressing binge eating. Hormone replacement therapy using estrogen may be a possible treatment for binge eating behaviors in females. Estrogen replacement has been shown to suppress binge eating behaviors in female mice. The mechanism by which estrogen replacement inhibits binge-like eating involves the replacement of serotonin (5-HT) neurons. Women exhibiting binge eating behaviors are found to have increased brain uptake of neuron 5-HT, and therefore less of the neurotransmitter serotonin in the cerebrospinal fluid. Estrogen works to activate 5-HT neurons, leading to suppression of binge like eating behaviors. It is also suggested that there is an interaction between hormone levels and eating at different points in the female menstrual cycle. Research has predicted increased emotional eating during hormonal flux, which is characterized by high progesterone and estradiol levels that occur during the mid-luteal phase. It is hypothesized that these changes occur due to brain changes across the menstrual cycle that are likely a genomic effect of hormones. These effects produce menstrual cycle changes, which result in hormone release leading to behavioral changes, notably binge and emotional eating. These occur especially prominently among women who are genetically vulnerable to binge eating phenotypes. Binge eating is associated with decreased estradiol and increased progesterone. Klump et al.
Yohimbine is a substance found in the bark of yohim trees in West Africa. It was traditionally used in West African cultures, in which the bark would be boiled and the resulting water drunk until it increased sexual desire. It is also found in over-the-counter health products. Yohimbine is an indole alkaloid and is an adrenoceptor antagonist. Known adverse effects include nausea, anxiety, irregular heartbeats, and restlessness.
==== Alcohol metabolism ==== The best-known consequence of ALDH2 dysfunction is in relation to the consumption of ethanol. People heterozygous or homozygous for the ALDH2*2 metabolize ethanol to acetaldehyde normally but metabolize acetaldehyde poorly. As a result, they accumulate increased levels of acetaldehyde after consumption of alcoholic beverages. Effects include facial flushing (i.e. the "alcohol flush reaction"), urticaria, systemic dermatitis, and alcohol-induced respiratory reactions such as rhinitis and the exacerbation of asthma bronchoconstriction. The cited allergic reaction-like symptoms: (a) do not appear due to classical IgE or T cell-related allergen-induced reactions but rather the actions of acetaldehyde in stimulating the release of histamine, a probable mediating cause of these symptoms; (b) typically occur within 30–60 minutes of ingesting alcoholic beverages; and (c) occur in other Asian as well as non-Asian individuals that are either seriously defective in metabolizing ingested ethanol past acetaldehyde to acetic acid or, alternatively, that metabolize ethanol too rapidly for ALDH2 processing. People with a genetic ALDH2*2 deficiency have historically had a lower likelihood of developing alcoholism, both from stronger adverse effects and a possible reduction of dopamine release. However, this effect is not absolute: during the 1980s, there has been a steady increase in the number of Japanese alcoholics who carry the ALDH2*2 mutation. A strong social pressure to drink have overcome this genetic barrier to alcoholism.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.